

Appendiks til Karen Astrid Boldingh Debernard, Tone Westergren, Henning Gustav Økland, Anne Katrine Eek. Ketamin mot depresjon – et kritisk blikk. Tidsskr Nor Legeforen 2026; 146. doi: 10.4045/tidsskr.25.0739. Dette appendikset er et tillegg til artikkelen og er ikke bearbeidet redaksjonelt.

Referanseliste vurderte ketaminstudier

1. Anand A, Mathew SJ, Sanacora G, et al. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. *N Engl J Med.* 2023 Jun 22;388(25):2315-2325. doi: 10.1056/NEJMoa2302399.
2. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. *Biol Psychiatry.* 2000 Feb 15;47(4):351-4. doi: 10.1016/s0006-3223(99)00230-9.
3. Dwyer JB, Landeros-Weisenberger A, Johnson JA, et al. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. *Am J Psychiatry.* 2021 Apr 1;178(4):352-362. doi: 10.1176/appi.ajp.2020.20010018.
4. Ekstrand J, Fattah C, Persson M, et al. Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT). *Int J Neuropsychopharmacol.* 2022 May 27;25(5):339-349. doi: 10.1093/ijnp/pyab088
5. Fava M, Freeman MP, Flynn M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). *Mol Psychiatry.* 2020 Jul;25(7):1592-1603. doi: 10.1038/s41380-018-0256-5.
6. Ghasemi M, Kazemi MH, Yoosefi A, et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. *Psychiatry Res.* 2014 Feb 28;215(2):355-61. doi: 10.1016/j.psychres.2013.12.008.
7. Ionescu DF, Bentley KH, Eikermann M, et al. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. *J Affect Disord.* 2019 Jan 15;243:516-524. doi: 10.1016/j.jad.2018.09.037.
8. Jelovac A, McCaffrey C, Terao M, et al. Serial ketamine infusions as adjunctive therapy to inpatient care for depression: The KARMA-Dep 2 randomized clinical trial. *JAMA Psychiatry* 2025; 22: e253019.
9. Lai R, Katalinic N, Glue P, et al. Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. *World J Biol Psychiatry.* 2014 Sep;15(7):579-84. doi: 10.3109/15622975.2014.922697.
10. Lii TR, Smith AE, Flohr JR, et al. Randomized trial of ketamine masked by surgical anesthesia in patients with depression. *Nat Ment Health.* 2023 Nov;1(11):876-886. doi: 10.1038/s44220-023-00140-x.
11. Lijffijt M, Murphy N, Iqbal S, et al. Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial. *Neuropsychopharmacology.* 2022 Apr;47(5):1088-1095. doi: 10.1038/s41386-021-01242-9.
12. Loo CK, Gálvez V, O'Keefe E, et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. *Acta Psychiatr Scand.* 2016 Jul;134(1):48-56. doi: 10.1111/acps.12572.
13. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. *Am J Psychiatry.* 2013 Oct;170(10):1134-42. doi: 10.1176/appi.ajp.2013.13030392.

14. Phillips JL, Norris S, Talbot J, et al. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. *Am J Psychiatry*. 2019 May 1;176(5):401-409. doi: 10.1176/appi.ajp.2018.18070834.
15. Sharma RK, Kulkarni G, Kumar CN, et al. Antidepressant effects of ketamine and ECT: A pilot comparison. *J Affect Disord*. 2020 Nov 1;276:260-266. doi: 10.1016/j.jad.2020.07.066.
16. Shiroma PR, Thuras P, Wels J, et al. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. *Transl Psychiatry*. 2020 Jun 26;10(1):206. doi: 10.1038/s41398-020-00897-0.
17. Singh JB, Fedgchin M, Daly E, et al. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study. *Biol Psychiatry*. 2016 Sep 15;80(6):424-431. doi: 10.1016/j.biopsych.2015.10.018.
18. Singh JB, Fedgchin M, Daly EJ, et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. *Am J Psychiatry*. 2016 Aug 1;173(8):816-26. doi: 10.1176/appi.ajp.2016.16010037.
19. Sos P, Klirova M, Novak T, et al. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. *Neuro Endocrinol Lett*. 2013;34(4):287-93.
20. Su TP, Chen MH, Li CT, et al. Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression. *Neuropsychopharmacology*. 2017 Dec;42(13):2482-2492. doi: 10.1038/npp.2017.94.
21. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Arch Gen Psychiatry*. 2006 Aug;63(8):856-64. doi: 10.1001/archpsyc.63.8.856.
22. Zarate CA, Brutsche NE, Ibrahim L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. *Biol Psychiatry*. 2012 Jun 1;71(11):939-46. doi: 10.1016/j.biopsych.2011.12.010.